• Prospective cohort study to look at the impact of the choice of breast reconstruction (immediate, delayed or none) on quality-of-life measures and clinical outcomes for women undergoing mastectomy and PMRT for breast cancer (QoLID Study) • Investigate the effectiveness of using Denosumab to decrease or prevent the risk of developing breast cancer in women who carry a BRCA1 gene mutation (BRCA-P).
PUBLICATIONS
2024
Blank et al. 2024 “Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.” N Engl J Med 391: 1696-1708 PMID:38828984 Surgical Staff: Andrew Spillane Dempsey et al. 2024 “Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study.” Psychooncology 33: e70053 PMID:39694881 Surgical Staff: Andrew Spillane Gjorup et al. 2024 “Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.” Ann Surg Oncol 31: 1857-1864 PMID:37966706 Surgical Staff: Andrew Spillane Jiang et al. 2024 “Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review.” Eur J Surg Oncol 50: 108554 PMID:39059194 Surgical Staff: Andrew Spillane Lee et al. 2024 “ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.” Ann Surg Oncol 31: 4071-4072 PMID:38536583 Surgical Staff: Andrew Spillane Lee et al. 2024 “Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.” Ann Surg Oncol 31: 4061-4070 PMID:38494565 Surgical Staff: Andrew Spillane Long et al. 2024 “Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.” Nat Med 30: 2540-2548 PMID:38907159 Surgical Staff: Andrew Spillane Mann et al. 2024 “Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.” Lancet 403: 261-270 PMID:38065194 Surgical Staff: Andrew Spillane Menzies et al. 2024 “Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.” Ann Oncol 35: 739-746 PMID:38754780 Surgical Staff: Andrew Spillane Novis et al. 2024 “Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.” Eur J Surg Oncol 51: 109538 PMID:39662108 Surgical Staff: Andrew Spillane Ofri et al. 2024 “Optimising the targeted axillary dissection in breast cancer: marker type and timing variability.” Gland Surg 13: 1878-1882 PMID:39544982 Surgical Staff: Andrew Spillane Ofri et al. 2024 “Current bi-national attitudes towards targeted axillary dissection.” ANZ J Surg 94: 11-13 PMID:38149761 Surgical Staff: Andrew Spillane Ofri et al. 2024 “The complexities of establishing a surgical multi-centre registry in Australia: challenges, and possible solution.” ANZ J Surg 94: 1444-1446 PMID:38995075 Surgical Staff: Andrew Spillane Potter et al. 2024 “Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project.” BMJ Open 14: e084488 PMID:38643011 Surgical Staff: Andrew Spillane Reijers et al. 2024 “Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.” Eur J Cancer 214: 115141 PMID:39602990 Surgical Staff: Andrew Spillane Varey et al. 2024 “Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.” J Clin Oncol 42: 1169-1180 PMID:38315961 Surgical Staff: Andrew Spillane Winder et al. 2024 “ASO Author Reflections: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.” Ann Surg Oncol 31: 5352-5353 PMID:38874872 Surgical Staff: Andrew Spillane Winder et al. 2024 “Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.” Ann Surg Oncol 31: 5331-5339 PMID:38802717 Surgical Staff: Andrew Spillane
7
Made with FlippingBook - professional solution for displaying marketing and sales documents online